BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 3513943)

  • 1. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
    Omura G; Blessing JA; Ehrlich CE; Miller A; Yordan E; Creasman WT; Homesley HD
    Cancer; 1986 May; 57(9):1725-30. PubMed ID: 3513943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
    Omura GA; Bundy BN; Berek JS; Curry S; Delgado G; Mortel R
    J Clin Oncol; 1989 Apr; 7(4):457-65. PubMed ID: 2926470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
    Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
    Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
    J Clin Oncol; 1991 Sep; 9(9):1668-74. PubMed ID: 1831495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
    Bertelsen K; Jakobsen A; Strøyer J; Nielsen K; Sandberg E; Andersen JE; Ahrons S; Nyland M; Hjortkjaer Pedersen P; Larsen G
    Gynecol Oncol; 1993 Apr; 49(1):30-6. PubMed ID: 8482557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer.
    Hernádi Z; Juhász B; Póka R; Lampé LG
    Int J Gynaecol Obstet; 1988 Oct; 27(2):199-204. PubMed ID: 2903085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III and IV suboptimal disease ovarian cancer: a Southwest Oncology Group Study.
    Alberts DS; Mason-Liddil N; O'Toole RV; Abbott TM; Kronmal R; Hilgers RD; Surwit EA; Eyre HJ; Baker LH
    Gynecol Oncol; 1989 Jan; 32(1):8-15. PubMed ID: 2642455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
    Greco FA; Johnson DH; Hainsworth JD
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
    Hakes TB; Chalas E; Hoskins WJ; Jones WB; Markman M; Rubin SC; Chapman D; Almadrones L; Lewis JL
    Gynecol Oncol; 1992 Jun; 45(3):284-9. PubMed ID: 1612505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study.
    de Oliveira CF; Lacave AJ; Villani C; Wolff JP; di Re F; Namer M; Maskens A; George M; Dalesio O; Rotmensz N
    Eur J Gynaecol Oncol; 1990; 11(5):323-30. PubMed ID: 2097149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, adriamycin and cyclophosphamide (PACe) combination chemotherapy in patients with ovarian carcinoma resistant to chlorambucil.
    Mead GM; Williams CJ; Whitehouse JM
    Cancer Chemother Pharmacol; 1985; 15(2):179-80. PubMed ID: 3839443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.
    Bertelsen K; Jakobsen A; Andersen JE; Ahrons S; Pedersen PH; Kiaer H; Arffmann E; Bichel P; Boestofte E; Strøyer I
    Gynecol Oncol; 1987 Oct; 28(2):161-9. PubMed ID: 3311924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide, adriamycin and cisplatin (CAP) versus cyclophosphamide, adriamycin and vincristin (CAV) in the treatment of advanced ovarian cancer: a randomized study.
    Krommer CF; Szalai JP
    Ann Oncol; 1992 Jan; 3(1):37-9. PubMed ID: 1606067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.